PPARγ agonists, TZDs, induced ADP expression and secretion in a dose- and time-dependent manner in humans and rodents in vitro and in vivo and suppressed the growth, migration, and invasion of cancer cells by augmenting ADP expression and inhibiting leptin signaling [276,277]. The gene discussed is LEP; the disease is cancer.